Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer

6392.50
0.50%
Hem Securities
Total Revenue stood at Rs 1987.51 Cr for Q2FY22, registering a growth of 13.6% YoY. Profit for the period increased 16.7% YoY to Rs. 606.46 Cr. Operating Margins slightly weak at 51.9% in Q2FY22 against 52.5% in corresponding period last year. Cash flow from Operations stood at Rs. 557.22 Cr in H1FY22. The company completed debottlenecking and expansion of plants which got delayed due to the pandemic. However, rising raw material prices and...
Divi's Laboratories Ltd. is trading above its 200 day SMA of 6304.5
More from Divi's Laboratori…
All earning calls
Investor presentations from Divi's Laboratori…
All investor presentations